<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8806548</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21560</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Neuropsychol</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Neuropsychol</journal-id>
<journal-title-group>
<journal-title>The Clinical neuropsychologist</journal-title>
</journal-title-group>
<issn pub-type="ppub">1385-4046</issn>
<issn pub-type="epub">1744-4144</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27414076</article-id>
<article-id pub-id-type="pmc">7336900</article-id>
<article-id pub-id-type="doi">10.1080/13854046.2016.1202239</article-id>
<article-id pub-id-type="manuscript">NIHMS812197</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fragile X-associated Tremor/Ataxia Syndrome: Phenotypic comparisons with other Movement Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Robertson</surname>
<given-names>Erin E.</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hall</surname>
<given-names>Deborah A.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McAsey</surname>
<given-names>Andrew R.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Keefe</surname>
<given-names>Joan A.</given-names>
</name>
<degrees>PhD, PT</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Anatomy and Cell Biology, Rush University, Chicago, IL</aff>
<aff id="A2"><label>2</label>Department of Neurological Sciences, Rush University, Chicago, IL</aff>
<author-notes>
<fn fn-type="other" id="FN1">
<p id="P1">All other author information:</p>
<p id="P2">Erin Robertson, BA, Department of Anatomy and Cell Biology, Rush University, 600 South Paulina Street, Chicago, IL 60612, T 312-942-5501</p>
<p id="P3">Andrew R. McAsey, BS, Department of Anatomy and Cell Biology, Rush University, 600 South Paulina Street, Chicago, IL 60612, T 312-942-5501</p>
<p id="P4">Deborah Hall, MD PhD, 1725 West Harrison, Suite 755, Chicago, IL 60611, T 312-563-2900, F 312-563-2184</p>
</fn>
<fn fn-type="other" id="FN5">
<p id="P5">Author disclosures:</p>
<p id="P6">Erin Robertson reports no disclosures.</p>
<p id="P7">Deborah A. Hall has received research funds from NINDS, Shapiro Foundation, National Parkinson Disease Foundation, Pfizer, and Neurocrine.</p>
<p id="P8">Andrew McAsey reports no disclosures.</p>
<p id="P9">Joan A. O’Keefe reports no disclosures.</p>
</fn>
<fn fn-type="con" id="FN10">
<p id="P10">Author contributions:</p>
<p id="P11">Erin Robertson (ER)</p>
<p id="P12">Deborah Hall (DH)</p>
<p id="P13">Andrew McAsey (AM)</p>
<p id="P14">Joan O’Keefe (JO)
<list id="L3" list-type="order"><list-item><p id="P15">Research project: A. Conception: B. Organization: C. Execution: ER, DH, JO</p></list-item><list-item><p id="P16">Manuscript Preparation: A. Writing of the first draft: ER, JO; B. Review and Critique: ER, DH, AM, JO</p></list-item></list></p>
</fn>
<corresp id="CR1">Corresponding author: Joan Ann O’Keefe, PhD, PT, Department of Anatomy and Cell Biology, Rush University, 600 South Paulina Street, 507 B, Chicago, IL 60612, T 312-563-3940, F 312-942-5744, <email>Joan_A_O’Keefe@Rush.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>21</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>7</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<issue>6</issue>
<fpage>849</fpage>
<lpage>900</lpage>
<!--elocation-id from pubmed: 10.1080/13854046.2016.1202239-->
<abstract id="ABS1">
<sec id="S1">
<title>Objective:</title>
<p id="P17">The purpose of this paper is to review the typical cognitive and motor impairments seen in fragile X-associated tremor/ataxia syndrome (FXTAS), essential tremor (ET), Parkinson disease (PD), spinocerebellar ataxias (SCAs), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) in order to enhance diagnosis of FXTAS patients.</p>
</sec>
<sec id="S2">
<title>Method:</title>
<p id="P18">We compared the cognitive and motor phenotypes of FXTAS with each of these other movement disorders. Relevant neuropathological and neuroimaging findings are also reviewed. Finally, we describe the differences in age of onset, disease severity, progression rates and average lifespan in FXTAS compared to ET, PD, SCAs, MSA and PSP. We conclude with a flow chart algorithm to guide the clinician in the differential diagnosis of FXTAS.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P19">By comparing the cognitive and motor phenotypes of FXTAS with the phenotypes of ET, PD, SCAs, MSA, and PSP we have clarified potential symptom overlap while elucidating factors that make these disorders unique from one another. In summary, the clinician should consider a FXTAS diagnosis and testing for the Fragile X mental retardation 1 (<italic>FMR1)</italic> gene premutation if a patient over the age of 50 (1) presents with cerebellar ataxia and/or intention tremor with mild parkinsonism, (2) has the middle cerebellar peduncle (MCP) sign, global cerebellar and cerebral atrophy, and/or subcortical white matter lesions on MRI, or (3) has a family history of fragile X related disorders, intellectual disability, autism, premature ovarian failure and has neurological signs consistent with FXTAS. Peripheral neuropathy, executive function deficits, anxiety, or depression are supportive of the diagnosis.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P20">Distinct profiles in the cognitive and motor domains between these movement disorders may guide practitioners in the differential diagnosis process and ultimately lead to better medical management of FXTAS patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>FXTAS</kwd>
<kwd>essential tremor</kwd>
<kwd>Parkinson disease</kwd>
<kwd>spinocerebellar ataxia</kwd>
<kwd>multiple system atrophy</kwd>
<kwd>progressive supranuclear palsy</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>